New hormone and immunotherapy trial for breast cancer patients
October 8, 2018
| by City of Hope
The complementary modes of action and the low potential for overlapping toxicity make the combination of androgen receptor (AR) targeted therapy and immunotherapy one of the most promising treatment strategies for metastatic triple-negative breast cancer, which accounts for 15 to 20 percent of all breast cancers. These may also be more patient-friendly therapies as their mechanisms of action are not associated with the alopecia of traditional therapies.
An open-label phase 2 clinical trial is evaluating the combination of pembrolizumab and selective AR modulator GTx-024 in patients with advanced AR-positive triple-negative breast cancer. The primary endpoint is the safety and tolerability of the treatment regimen, as well as the response rate (CR or PR via RECIST 1.1). Clinical benefit rate, duration of response, progression-free survival and overall survival will also be used to measure efficacy.
For enrollment information, please contact Yuan by phone at 626-256-4673, ext. 89200, or by email at [email protected]
, Thank you for subscribing to Physician News.
Check your inbox for the latest breakthroughs, clinical trials, and CME opportunities.
, Unable to process your request. We're sorry for the inconvenience. Please try after sometime.
You may also be interested in